Vertrix Wealth Management LLC Invests $5.44 Million in Amgen Inc. $AMGN

Posted by Grant Hamersma on Jul 2nd, 2026

Vertrix Wealth Management LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the 1st quarter, Holdings Channel.com reports. The fund purchased 15,456 shares of the medical research company’s stock, valued at approximately $5,438,000. Amgen accounts for about 2.0% of Vertrix Wealth Management LLC’s portfolio, making the stock its 13th biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Whelan Financial bought a new position in Amgen in the 1st quarter worth approximately $217,000. USS Investment Management Ltd boosted its position in Amgen by 4.0% in the 1st quarter. USS Investment Management Ltd now owns 95,031 shares of the medical research company’s stock valued at $33,424,000 after buying an additional 3,681 shares during the last quarter. IFM Investors Pty Ltd increased its stake in shares of Amgen by 2.9% in the 1st quarter. IFM Investors Pty Ltd now owns 109,804 shares of the medical research company’s stock valued at $38,635,000 after buying an additional 3,051 shares during the period. Rexford Capital Inc. increased its stake in shares of Amgen by 0.9% in the 1st quarter. Rexford Capital Inc. now owns 5,456 shares of the medical research company’s stock valued at $1,920,000 after buying an additional 46 shares during the period. Finally, Key Financial Inc raised its position in shares of Amgen by 32.4% during the first quarter. Key Financial Inc now owns 1,545 shares of the medical research company’s stock worth $544,000 after acquiring an additional 378 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.2%

Amgen stock opened at $361.33 on Thursday. The firm has a market capitalization of $195.01 billion, a price-to-earnings ratio of 25.14, a PEG ratio of 3.56 and a beta of 0.41. The company’s 50 day simple moving average is $341.28 and its 200 day simple moving average is $347.34. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.39 EPS for the current year.

More Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: A federal judge blocked Colorado’s first-of-its-kind price cap on Enbrel, easing a potentially important state-level pricing overhang for one of Amgen’s blockbuster drugs. Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel
Positive Sentiment: Amgen’s pipeline remains a point of investor interest, with commentary highlighting MariTide and olpasiran as potential growth drivers and a study update on evolocumab reinforcing focus on the PCSK9 franchise. Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study
Positive Sentiment: Analyst coverage continues to view Amgen favorably versus peers, citing its broader product mix, deeper pipeline, and steadier growth outlook. Amgen or Biogen: Which Biotech Stock Appears Better Poised?
Neutral Sentiment: Investor attention on AMGN has been elevated, which can reflect anticipation around upcoming catalysts but does not by itself change fundamentals. Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Negative Sentiment: Regulatory pressure remains a key risk, as European regulators have recommended revoking Tavneos’ marketing authorization and a journal retraction further weakens the drug’s case for continued use. Amgen (AMGN) Faces EU Push To Revoke Tavneos Approval Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group upped their price target on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Thursday, June 18th. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a research report on Thursday, June 18th. Finally, Wells Fargo & Company lifted their price target on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $355.50.

Get Our Latest Research Report on Amgen

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.